Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for OUD and Suicidal Ideation in ED
NCT06111339Phase 2Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in opioid use disorder (OUD) and suicidal ideation comparing Ketamine with Saline Placebo (2 arms). Primary endpoints: Lower Suicidal Ideation at 28 days, Less Illicit Opioid Use at 28 days and 1 more. Started Jun 2024; status: terminated.
02
Drugs
ketamine
03
Conditions
opioid use disorder (OUD)suicidal ideation
Beyond the preview
Go deeper on NCT06111339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111339.